Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Minimal Change Disease

Minimal Change Disease

Part of Kidney Diseases

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Minimal Change Disease

3 trials tracked for Minimal Change Disease: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 19 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 2 2
  1. Phase 4 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease Completed · 19 cited
  2. Phase 2 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Completed
  3. Phase 2 Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome
Rheumatology Cohort
Rituximab Shows Long-Term Remission in Pediatric Steroid-Dependent Nephrotic Syndrome Rituximab Helps Kids With Kidney Swelling
This retrospective cohort study of 42 children with steroid-dependent or frequently relapsing nephrotic syndrome found that rituximab led to…
Imagine a child who needs medicine just to stay dry.
Frontiers Apr 24, 2026
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Drug Pipeline Cohort
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Frontiers Apr 19, 2026
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD
Nephrology Phase II
Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD Could New Treatments Help Those Struggling with Kidney Disease?
A Phase 2a trial is assessing frexalimab, brivekimig, and rilzabrutinib for reducing proteinuria in FSGS and MCD. Primary outcome is the per…
New kidney treatments aim to reduce urine protein and improve daily life for patients with FSGS or minimal change disease.
CT.gov Mar 27, 2026

Questions about Minimal Change Disease

How does rituximab work differently in Minimal Change Disease versus other kidney diseases?

Rituximab works by depleting B-cells to reduce inflammation in Minimal Change Disease (MCD), but its effectiveness and how the body clears the drug differ from other kidney diseases like FSGS or Lupus due to unique factors like protein loss and genetics.

Full answer →